Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.


TSXV:HEM - Post by User

Bullboard Posts
Post by dt_coreon Sep 25, 2012 5:35pm
399 Views
Post# 20413297

Another New Patent

Another New Patent

Hemisphere GPS Assigned Patent ALEXANDRIA, Va., Sept. 25 -- Hemisphere GPS, Calgary, Alberta, Canada, has been assigned a patent (8,271,194) developed by five co-inventors for a "method and system using GNSS phase measurements for relative positioning." The co-inventors are Michael L. Whitehead, Scottsdale, Ariz., Steven R. Miller, Scottsdale, Ariz., John A. McClure, Scottsdale, Ariz., Cary Davis, Cave Creek, Ariz., and Walter J. Feller, Airdrie, Calif.

The abstract of the patent published by the U.S. Patent and Trademark Office states: "A method for locating GNSS-defined points, distances, directional attitudes and closed geometric shapes includes the steps of providing a base with a base GNSS antenna and providing a rover with a rover GNSS antenna and receiver. The receiver is connected to the rover GNSS antenna and is connected to the base GNSS antenna by an RF cable. The receiver thereby simultaneously processes signals received at the antennas. The method includes determining a vector directional arrow from the differential positions of the antennas and calculating a distance between the antennas, which can be sequentially chained together for determining a cumulative distance in a "digital tape measure" mode of operation. A localized RTK surveying method uses the rover antenna for determining relative or absolute point locations. A system includes a base with an antenna, a rover with an antenna and a receiver, with the receiver being connected to the antennas. A processor is provided for computing positions, directional vectors, areas and other related tasks."

Bullboard Posts